Advertisement

ىاسمىن

المعلومات الرئيسية

  • اسم تجاري:
  • ىاسمىن
  • الشكل الصيدلاني:
  • FILM COATED TABLETS
  • طريقة التعاطي:
  • PER OS
  • يسخدم من اجل:
  • البشر
  • نوع الدواء:
  • المخدرات الوباتشيك
  • المصنعة من قبل:
  • BAYER PHARMA AG, GERMANY
Advertisement

المستندات

  • لعامة الناس:
  • النشرة المعلومات عن هذا المنتج غير متوفر حاليا، يمكنك إرسال طلب لخدمة العملاء لدينا، ونحن سوف يخطر لك في أقرب وقت ونحن قادرون على الحصول عليه.


    طلب نشرة المعلومات لعامة الناس.

الأقلمة

  • متاح في:
  • ىاسمىن
    إسرائيل
  • اللغة:
  • العربية

معلومات العلاجية

  • المجموعة العلاجية:
  • DROSPIRENONE AND ESTROGEN
  • الخصائص العلاجية:
  • Oral contraception.

معلومات أخرى

الحالة

  • المصدر:
  • Ministry of Health - State of Israel
  • تخويل:
  • 122023022000
  • تاريخ الترخيص:
  • 01-04-2011
  • اخر تحديث:
  • 09-08-2016
  • النشرة المعلومات عن هذا المنتج غير متوفر حاليا، يمكنك إرسال طلب لخدمة العملاء لدينا، ونحن سوف يخطر لك في أقرب وقت ونحن قادرون على الحصول عليه.

    طلب نشرة المعلومات لعامة الناس.



  • وثائق في اللغات الأخرى المتاحة هنا

13-2-2018

FDA Drug Safety Communication: UPDATE on Tumor Necrosis Factor (TNF) blockers and risk for pediatric malignancy

FDA Drug Safety Communication: UPDATE on Tumor Necrosis Factor (TNF) blockers and risk for pediatric malignancy

[11-03-2011] The U.S. Food and Drug Administration (FDA) is updating the public about its ongoing safety review of Tumor Necrosis Factor (TNF) blockers and malignancy (cancer) in children, adolescents, and young adults (30 years of age or younger).

FDA - U.S. Food and Drug Administration

9-2-2018

FDA Drug Safety Communication: Safety review update on the possible increased risk of blood clots with birth control pills containing drospirenone

FDA Drug Safety Communication: Safety review update on the possible increased risk of blood clots with birth control pills containing drospirenone

[09-26-2011] The U.S. Food and Drug Administration (FDA) is informing the public that it has not yet reached a conclusion, but remains concerned, about the potential increased risk of blood clots with the use of drospirenone-containing birth control pills.

FDA - U.S. Food and Drug Administration

19-1-2018

Scientific guideline:  Guideline on the chemistry of active substances for veterinary medicinal products, adopted

Scientific guideline: Guideline on the chemistry of active substances for veterinary medicinal products, adopted

Guideline concerning the application of Directive 2001/82/EC with a view to the granting of a marketing authorisation for a veterinary medicinal product. This guideline replaces the ‘Note for guidance on chemistry of new active substances’ (EMEA/CVMP/541/03/Final) and ‘Chemistry of active substances’ (3AQ5a). It has been revised to cover new and existing active substances in one guideline.

Europe - EFSA - European Food Safety Authority EFSA Journal

3-1-2018

Enforcement Report for the Week of January 03, 2018

Enforcement Report for the Week of January 03, 2018

FDA - U.S. Food and Drug Administration

13-12-2017

FDA Drug Safety Communication: Updated information about the FDA-funded study on risk of blood clots in women taking birth control pills containing drospirenone

FDA Drug Safety Communication: Updated information about the FDA-funded study on risk of blood clots in women taking birth control pills containing drospirenone

[10-27-2011] The U.S. Food and Drug Administration (FDA) is continuing its review of the potential increased risk of blood clots with the use of birth control pills containing drospirenone.

FDA - U.S. Food and Drug Administration

11-12-2017

FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use

FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use

[03-03-2015] The U.S. Food and Drug Administration (FDA) cautions that prescription testosterone products are approved only for men who have low testosterone levels caused by certain medical conditions.

FDA - U.S. Food and Drug Administration

11-12-2017

FDA Drug Safety Communication: FDA updates label for stop smoking drug Chantix (varenicline) to include potential alcohol interaction, rare risk of seizures, and studies of side effects on mood, behavior, or thinking

FDA Drug Safety Communication: FDA updates label for stop smoking drug Chantix (varenicline) to include potential alcohol interaction, rare risk of seizures, and studies of side effects on mood, behavior, or thinking

[03-09-2015] The U.S. Food and Drug Administration (FDA) is warning that the prescription smoking cessation medicine Chantix (varenicline) can change the way people react to alcohol.

FDA - U.S. Food and Drug Administration

11-12-2017

FDA Drug Safety Communication: FDA review of study sheds light on two deaths associated with the injectable schizophrenia drug Zyprexa Relprevv (olanzapine pamoate)

FDA Drug Safety Communication: FDA review of study sheds light on two deaths associated with the injectable schizophrenia drug Zyprexa Relprevv (olanzapine pamoate)

[03-23-2015] The U.S. Food and Drug Administration (FDA) has concluded a review of a study undertaken to determine the cause of elevated levels of the injectable schizophrenia drug Zyprexa Relprevv (olanzapine pamoate) in two patients who died.

FDA - U.S. Food and Drug Administration

11-12-2017

FDA Drug Safety Communication: Avandia (rosiglitazone) labels now contain updated information about cardiovascular risks and use in certain patients

FDA Drug Safety Communication: Avandia (rosiglitazone) labels now contain updated information about cardiovascular risks and use in certain patients

[2-03-2011] The U.S. Food and Drug Administration (FDA) is notifying the public that information on the cardiovascular risks (including heart attack) of the diabetes drug rosiglitazone has been added to the physician labeling and patient Medication Guide.

FDA - U.S. Food and Drug Administration

11-12-2017

FDA Drug Safety Communication: Safety Review of possible increased risk of blood clots with birth control pills containing drospirenone

FDA Drug Safety Communication: Safety Review of possible increased risk of blood clots with birth control pills containing drospirenone

[05-31-2011] The U.S. Food and Drug Administration (FDA) is informing the public about new information that is being assessed as part of FDA's ongoing safety review of birth control pills that contain drospirenone.

FDA - U.S. Food and Drug Administration

4-8-2017

FDA Drug Safety Communication: Risk of oral clefts in children born to mothers taking Topamax (topiramate)

FDA Drug Safety Communication: Risk of oral clefts in children born to mothers taking Topamax (topiramate)

[03-04-2011] The U.S. Food and Drug Administration (FDA) is informing the public of new data that show that there is an increased risk for the development of cleft lip and/or cleft palate (oral clefts) in infants born to women treated with Topamax (topiramate) during pregnancy.

FDA - U.S. Food and Drug Administration

4-8-2017

FDA Drug Safety Communication: Special storage and handling requirements must be followed for Pradaxa (dabigatran etexilate mesylate) capsules

FDA Drug Safety Communication: Special storage and handling requirements must be followed for Pradaxa (dabigatran etexilate mesylate) capsules

[03-29-2011] The U.S. Food and Drug Administration (FDA) is alerting the public to important storage and handling requirements for Pradaxa (dabigatran etexilate mesylate) capsules.

FDA - U.S. Food and Drug Administration

4-8-2017

FDA Drug Safety Communication:Use of long-term, high-dose Diflucan (fluconazole) during pregnancy may be associated with birth defects in infants

FDA Drug Safety Communication:Use of long-term, high-dose Diflucan (fluconazole) during pregnancy may be associated with birth defects in infants

[8-03-2011] The U.S. Food and Drug Administration (FDA) is informing the public that chronic, high doses (400-800 mg/day) of the antifungal drug Diflucan (fluconazole) may be associated with a rare and distinct set of birth defects in infants whose mothers were treated with the drug during the first trimester of pregnancy.

FDA - U.S. Food and Drug Administration

3-8-2017

FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug

FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug

[03-12-2010] The U.S. Food and Drug Administration (FDA) has added a Boxed Warning to the label for Plavix, the anti-blood clotting medication.

FDA - U.S. Food and Drug Administration

3-8-2017

FDA Drug Safety Communication: Ongoing Safety Review of Stalevo (entacapone/carbidopa/levodopa) and possible development of Prostate Cancer

FDA Drug Safety Communication: Ongoing Safety Review of Stalevo (entacapone/carbidopa/levodopa) and possible development of Prostate Cancer

[03-31-2010] The U.S. Food and Drug Administration (FDA) is evaluating clinical trial data that may suggest that patients taking Stalevo, a Parkinson's disease medication, may be at an increased risk for developing prostate cancer.

FDA - U.S. Food and Drug Administration

9-2-2018

DROSPIRENONE AND ETHINYL ESTRADIOL Kit [Mylan Pharmaceuticals Inc.]

DROSPIRENONE AND ETHINYL ESTRADIOL Kit [Mylan Pharmaceuticals Inc.]

Updated Date: Feb 9, 2018 EST

US - DailyMed

6-2-2018

EU/3/07/478 (ICON Clinical Research Limited)

EU/3/07/478 (ICON Clinical Research Limited)

EU/3/07/478 (Active substance: N- (2-Amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide) - Transfer of orphan designation - Commission Decision (2018)697 of Tue, 06 Feb 2018 European Medicines Agency (EMA) procedure number: EMA/OD/053/07/T/03

Europe -DG Health and Food Safety

5-2-2018

EU/3/07/526 (ICON Clinical Research Limited)

EU/3/07/526 (ICON Clinical Research Limited)

EU/3/07/526 (Active substance: N- (2-Amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide) - Transfer of orphan designation - Commission Decision (2018)698 of Mon, 05 Feb 2018 European Medicines Agency (EMA) procedure number: EMA/OD/099/07/T/03

Europe -DG Health and Food Safety

23-1-2018

VESTURA (Drospirenone And Ethinyl Estradiol) Kit [Actavis Pharma, Inc.]

VESTURA (Drospirenone And Ethinyl Estradiol) Kit [Actavis Pharma, Inc.]

Updated Date: Jan 23, 2018 EST

US - DailyMed

22-12-2017

3LAB PERFECT BB SPF 40 BROAD SPECTRUM 03 (Titanium Dioxide) Cream [3LAB, Inc]

3LAB PERFECT BB SPF 40 BROAD SPECTRUM 03 (Titanium Dioxide) Cream [3LAB, Inc]

Updated Date: Dec 22, 2017 EST

US - DailyMed

22-12-2017

3LAB AQUA BB SPF 40 BROAD SPECTRUM 03 (Titanium Dioxide) Cream [3LAB, Inc.]

3LAB AQUA BB SPF 40 BROAD SPECTRUM 03 (Titanium Dioxide) Cream [3LAB, Inc.]

Updated Date: Dec 22, 2017 EST

US - DailyMed

22-12-2017

SYEDA (Drospirenone And Ethinyl Estradiol) Kit [Sandoz Inc]

SYEDA (Drospirenone And Ethinyl Estradiol) Kit [Sandoz Inc]

Updated Date: Dec 22, 2017 EST

US - DailyMed

18-12-2017

 Minutes of the European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting, 25 October 2017

Minutes of the European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting, 25 October 2017

Minutes - Enpr-EMA Coordinating Group and networks meeting, Wednesday 25 October 2017, EMA room 03-H and via Adobe Connect; 15.00 to 17:00 UK time

Europe - EMA - European Medicines Agency

18-12-2017

Agenda:  Agenda - European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting, 25 October 2017

Agenda: Agenda - European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting, 25 October 2017

Agenda - Enpr-EMA Coordinating Group and networks meeting, Wednesday 25 October 2017, EMA room 03-H and via Adobe Connect; 15.00 to 17:00 UK time

Europe - EMA - European Medicines Agency

18-12-2017

Agenda:  Agenda - European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting

Agenda: Agenda - European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting

Agenda - Enpr-EMA Coordinating Group meeting, Wednesday 22 November 2017, EMA room 03-H and via Adobe Connect; 15.00 to 16:00 UK time

Europe - EMA - European Medicines Agency

18-12-2017

 Minutes of the European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting

Minutes of the European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting

Minutes - Enpr-EMA Coordinating Group meeting, Wednesday 22 November 2017, EMA room 03-H and via Adobe Connect; 15.00 to 16:00 UK time

Europe - EMA - European Medicines Agency

18-12-2017

ZARAH (Drospirenone And Ethinyl Estradiol) Kit [Mayne Pharma Inc.]

ZARAH (Drospirenone And Ethinyl Estradiol) Kit [Mayne Pharma Inc.]

Updated Date: Dec 18, 2017 EST

US - DailyMed

12-12-2017

EU/3/05/272 (Noventia Pharma Srl)

EU/3/05/272 (Noventia Pharma Srl)

EU/3/05/272 (Active substance: Histamine dihydrochloride) - Transfer of orphan designation - Commission Decision (2017)8597 of Tue, 12 Dec 2017 European Medicines Agency (EMA) procedure number: EMEA/OD/094/04/T/03

Europe -DG Health and Food Safety

6-12-2017

Summer Skin Risks: Sunburn, Bug Bites & Poison Ivy

Summer Skin Risks: Sunburn, Bug Bites & Poison Ivy

Title: Summer Skin Risks: Sunburn, Bug Bites & Poison IvyCategory: MedicineNet QuizCreated: 8/17/2010 12:00:00 AMLast Editorial Review: 12/6/2017 6:04:03 PM

US - MedicineNet

21-11-2017

LORYNA (Drospirenone And Ethinyl Estradiol) Kit [Sandoz Inc]

LORYNA (Drospirenone And Ethinyl Estradiol) Kit [Sandoz Inc]

Updated Date: Nov 21, 2017 EST

US - DailyMed

7-11-2017

NIKKI ( Drospirenone And Ethinyl Estradiol ) Kit [Lupin Pharmaceuticals, Inc.]

NIKKI ( Drospirenone And Ethinyl Estradiol ) Kit [Lupin Pharmaceuticals, Inc.]

Updated Date: Nov 7, 2017 EST

US - DailyMed

26-10-2017

DROSPIRENONE AND ETHINYL ESTRADIOL Kit [Pharmaceutics International, Inc. (Pii)]

DROSPIRENONE AND ETHINYL ESTRADIOL Kit [Pharmaceutics International, Inc. (Pii)]

Updated Date: Oct 26, 2017 EST

US - DailyMed

25-10-2017

Insomnia Quiz: What Is Insomnia?

Insomnia Quiz: What Is Insomnia?

Title: Insomnia Quiz: What Is Insomnia?Category: MedicineNet QuizCreated: 6/6/2016 12:00:00 AMLast Editorial Review: 10/25/2017 2:47:03 PM

US - MedicineNet

17-10-2017

LUMASILK EMULSION LEVEL 03 Emulsion [The Skin Atelier, Inc.]

LUMASILK EMULSION LEVEL 03 Emulsion [The Skin Atelier, Inc.]

Updated Date: Oct 17, 2017 EST

US - DailyMed

18-9-2017

LIDOCARE 03 (4% Lidocaine Patch) Patch [NFI Consumer Products]

LIDOCARE 03 (4% Lidocaine Patch) Patch [NFI Consumer Products]

Updated Date: Sep 18, 2017 EST

US - DailyMed

15-9-2017

DROSPIRENONE AND ETHINYL ESTRADIOL Kit [Glenmark Pharmaceuticals Inc., USA]

DROSPIRENONE AND ETHINYL ESTRADIOL Kit [Glenmark Pharmaceuticals Inc., USA]

Updated Date: Sep 15, 2017 EST

US - DailyMed

7-9-2017

Thorinane (Techdow Pharma Netherlands B.V.)

Thorinane (Techdow Pharma Netherlands B.V.)

Thorinane (Active substance: enoxaparin sodium) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2017)6109 of Thu, 07 Sep 2017 European Medicines Agency (EMA) procedure number: EMEA/H/C/003795/T/03

Europe -DG Health and Food Safety

7-9-2017

EU/3/03/182 (Idorsia Pharmaceuticals Deutschland GmbH)

EU/3/03/182 (Idorsia Pharmaceuticals Deutschland GmbH)

EU/3/03/182 (Active substance: 5-methyl-pyridine-2-sulfonic acid {6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[2-(1H-tetrazol-5-yl)-pyridin-4-yl]-pyrimidin-4-yl}-amide sodium salt) - Transfer of orphan designation - Commission Decision (2017)6106 of Thu, 07 Sep 2017 European Medicines Agency (EMA) procedure number: EMEA/OD/057/03/T/02

Europe -DG Health and Food Safety

31-8-2017

OCELLA (Drospirenone And Ethinyl Estradiol) Kit [TEVA PHARMACEUTICALS USA, INC.]

OCELLA (Drospirenone And Ethinyl Estradiol) Kit [TEVA PHARMACEUTICALS USA, INC.]

Updated Date: Aug 31, 2017 EST

US - DailyMed

29-8-2017

YAZ (Drospirenone And Ethinyl Estradiol) Kit [Bayer HealthCare Pharmaceuticals Inc.]

YAZ (Drospirenone And Ethinyl Estradiol) Kit [Bayer HealthCare Pharmaceuticals Inc.]

Updated Date: Aug 29, 2017 EST

US - DailyMed

17-7-2017

Zalmoxis (MolMed S.p.A.)

Zalmoxis (MolMed S.p.A.)

Zalmoxis (Active substance: Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (?LNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)) - Centralised - Annual renewal - Commission Decision (2017) 5100 of Mon, 17 Jul 2017 European Medicines Agency (EMA) procedure number: EMEA/H/C/2801/R/03

Europe -DG Health and Food Safety

3-7-2017

IKERVIS (Santen Oy)

IKERVIS (Santen Oy)

IKERVIS (Active substance: Ciclosporin) - Centralised - Yearly update - Commission Decision (2017)4649 of Mon, 03 Jul 2017

Europe -DG Health and Food Safety

3-7-2017

Uptravi (Actelion Registration Ltd)

Uptravi (Actelion Registration Ltd)

Uptravi (Active substance: selexipag) - Centralised - 2-Monthly update - Commission Decision (2017)4648 of Mon, 03 Jul 2017 European Medicines Agency (EMA) procedure number: EMEA/H/C/3774/II/07

Europe -DG Health and Food Safety

3-7-2017

Besponsa (Pfizer Limited)

Besponsa (Pfizer Limited)

Besponsa (Active substance: inotuzumab ozogamicin) - Centralised - Authorisation - Commission Decision (2017)4655 of Mon, 03 Jul 2017 European Medicines Agency (EMA) procedure number: EMEA/H/C/4119

Europe -DG Health and Food Safety

3-7-2017

Ibandronic acid Sandoz (Sandoz GmbH)

Ibandronic acid Sandoz (Sandoz GmbH)

Ibandronic acid Sandoz (Active substance: Ibandronic acid) - Centralised - Yearly update - Commission Decision (2017)4657 of Mon, 03 Jul 2017

Europe -DG Health and Food Safety

3-7-2017

EQUIOXX (CEVA SANTE ANIMALE)

EQUIOXX (CEVA SANTE ANIMALE)

EQUIOXX (Active substance: Firocoxib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2017)4646 of Mon, 03 Jul 2017 European Medicines Agency (EMA) procedure number: EMEA/V/C/142/T/19

Europe -DG Health and Food Safety

Advertisement